Introduction
Actinic keratosis (AK) is a condition in which hyperplastic epidermal lesions develop in response to excessive and chronic exposure to ultraviolet (UV) radiation, which is also referred to as solar keratosis or senile keratosis. AK incidence is rising worldwide as a result of the progressive aging of populations and an increase in lifetime cumulative exposure to UV radiation. 1 This sustained exposure to nonionizing radiation can result in the development of squamous cell carcinoma (SCC), as the majority of SCCs progress from preexisting AKs. [2] [3] [4] Risk factors for AK include the following: Fitzpatrick Skin Types I and II (Caucasian population), gender (more common in males), age (individuals older than 30 years), geographic area (exposure to solar radiation), and immunocompromised patients. 5 AK lesions thereby manifest on sun-damaged skin, enabling identification of risk groups for SCC, basal cell carcinoma, and even melanoma. 6 Commonly found on sun-exposed skin, a typical primary lesion appears as a rough erythematous papule, white to yellow scaly macule, or a plaque on the face, scalp, and extremeties. 7, 8 Currently, various treatment options exist, which range from topical medications to light-based therapies and procedural modalities. These treatments can be grouped into two main categories: lesional therapies and field therapies. Lesional therapies, including cryotherapy and excisional therapies, are directed at individual AK lesions and are most frequently implemented when the burden of lesions is low. In contrast, field therapies, including ingenol mebutate (IM), topical imiquimod, topical 5-fluorouracil (5-FU), diclofenac sodium (DFS), and photodynamic therapy (PDT), are applied to a larger area of skin in an effort to target numerous lesions as well as subclinical disease. Although lesional therapies are localized, field therapies target a larger surface area and can also involve normal skin. The differences between these two may When drawing comparisons between the different methods, it is important to consider how method of application, cost, clinical response, and the incidence of adverse effects also contribute to the perceived success of treatment. AK has been proven to have a negative impact on patient quality of life (QoL). 10 Treatment of AK is often associated with both discomfort and cosmetic impact, which may influence patient satisfaction. 11 In this article, we review reported outcomes of the most commonly utilized treatments and discuss the results and methods used to assess patient satisfaction in the management of AK.
Topical treatments
Topical therapies for AK are significant because they target both visible and subclinical lesions. 10 These include those nonvisible lesions that exist among the areas of damaged skin surrounding the detectable AK lesion. The damaged skin may often appear deeply wrinkled or with spotted pigmentation. Studies also reveal that there is poor adherence to topical therapies, on account of the presence of side effects and prolonged treatment. [12] [13] [14] [15] [16] IM IM induces rapid necrosis of dysplastic AK keratinocytes and stimulates neutrophil-mediated antibody-dependent cellular cytotoxicity (ADCC) by acting as a protein kinase C (PKC) agonist. 17 This dual mechanism of action expedites the agent's therapeutic effect and allows for lesion destruction after a period as little as 2-3 days. 17 The potential for IM to improve both outcomes and patient satisfaction has been demonstrated in various trials for the treatment of AK. A prospective pilot study examined the effects of IM gel 0.015% when applied once daily for 3 consecutive days to 28 patients with AKs of the face and observed a significant increase in QoL (p = 0.031). 10 All study participants were Caucasian males, ≥65 years of age, with at least seven AKs on the face. The Skindex-16 survey was used at days 0 and 60 to assess patient satisfaction. This dermatologic questionnaire sought to determine the effects of AK on patient QoL in terms of symptoms, emotions, and functioning. Subjects noted their level of bothersomeness using a 0-6 numerical analog scale, ranging from "never bothered" to "always bothered." Results described a decrease in overall Skindex-16 score from 24.5 at day 0 to 15.5 at day 60, with reductions in all three subscales. 10 Statistical significance, however, was only noted in the emotions subscale (p = 0.011). 10 This increase in patient QoL was consistent with a 77% reduction in lesions (95% CI, 68%-86%). 9 Furthermore, QoL seemed to improve regardless of local skin reactions (LSR) severity.
Post hoc analyses performed for four, Phase III, multicenter, randomized, double-blind, vehicle-controlled trials (n = 1005) also revealed significant reductions in Skindex-16 bothersomeness scores (p < 0.0001) at day 57.
11
Patients applied either IM 0.015% once daily for 3 consecutive days for the face and scalp or IM 0.05% once daily for 2 consecutive days for the trunk and extremities. 11 While there was a significant association between change in overall Skindex-16 score and clearance in the face/scalp group (p = 0.0006), such was not the case in the trunk/extremities group, although there was a positive trend. 11 Subjects younger than 65 years of age in the face/scalp group experienced higher QoL improvement for the emotions domain (p = 0.004) and for overall change in score (p = 0.024). 11 The Treatment Satisfaction Questionnaire for Medication (TSQM) survey was used to evaluate effectiveness, side effects, convenience, and global satisfaction; results showed significant positive associations between TSQM score and the degree of clearance for patients in both the face/scalp group (effectiveness, p < 0.0001 and global satisfaction, p = 0.0002) and the trunk/extremities group (p < 0.0001 and p = 0.0014).
11 Still greater improvements were reported for the former, which corresponded to higher efficacy rates of treatment on the face/scalp when compared to other locations.
Imiquimod
Imiquimod, a synthetic nucleoside analog of the imidazoquinoline family, activates Toll-like receptors (TLR7/8) leading to the induction of the innate immune response. 18 Such a response enhances interferon (IFN), tumor necrosis factor (TNF), and interleukins 1 and 12 (IL-1/12) and further stimulates an acquired immune response through the activation of TH1 cells. 18 Topical application of imiquimod induces IFNα within AK lesions and subsequently triggers such innate and adaptive immune response. 19 An open-label, multicenter study with 118 AK patients utilized the Skindex-17 and TSQM surveys to assess how treatment with imiquimod cream 5% impacts patient-reported outcomes and health-related QoL (HRQoL) and found no clinically relevant impact. 20 However, HRQoL impairment was noted to be low even at baseline for both surveys. 20 Although literature assessing patient satisfaction with imiquimod as a treatment for AK is limited, various studies compare patient QoL and preference between imiquimod and other treatments. A prospective, nonrandomized pilot study found that although IM had a higher median Skindex-29 score for 
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Patient satisfaction and reported outcomes convenience of therapy (83.3), both imiquimod 5% and IM achieved higher median TSQM scores for effectiveness (72.7 for both) and global satisfaction (72.9 and 69.4, respectively) when compared to other therapies. 21 Imiquimod 5% also had the highest satisfaction scores with respect to side effects (median of 93.8). 21 In contrast to other topical treatments like IM, where LSR have been known to resolve by week 3, imiquimod side effects often peak during the first 2 weeks of treatment and resolve somewhere between 3-4 weeks after the therapy is complete. 22 In a prospective comparative study (n = 58) between 5% imiquimod cream and PDT with methyl aminolevulinate (MAL), patients reported no significant difference in tolerance of treatment, although 34% and 28% of patients described poor tolerance to PDT and imiquimod therapy, respectively. 23 However, satisfaction evaluations, which were conducted a month after cessation of treatment, showed that a higher percentage of patients treated with PDT were very satisfied when compared to those treated with imiquimod (93% versus 62%, p = 0.004). 23 Still, 72% of patients treated with imiquimod preferred being retreated with the same treatment. 23 
5-FU
5-FU is topically applied and inhibits thymidylate synthetase, an enzyme responsible for cell death and required for DNA synthesis. 24 The most common adverse effects include irritation of the skin, erythema, and dryness. 25 Patient satisfaction with 5-FU has been explored in one randomized, parallel group clinical trial comparing 5% 5-FU and 3% DFS, as described subsequently. 26 
DFS
DFS is topically applied and often associated with 2.5% hyaluronic acid. Although its mechanism of action is not entirely understood, it decreases arachidonic acid metabolite formation, which would normally inhibit apoptosis and increase angiogenesis. 27, 28 In a randomized, parallel-group clinical trial with 28 patients of both genders with at least five AKs on the face, scalp, or back of the hands, patient satisfaction for the treatment with 5% 5-FU and 3% DFS was reported in terms of satisfaction with adverse effects and lesion clearance. 26 Patients either applied 3% DFS gel twice daily for 12 weeks or 5% 5-FU cream twice daily for 4 weeks. As per patient testimony, 73% of those treated with DFS and 77% of those treated with 5-FU were highly satisfied, revealing no significant difference between the groups. 26 However, patients treated with DFS did report significantly higher satisfaction regarding adverse events (93.3% versus 38.4%, p = 0.008), since those treated with 5-FU observed more instances of erythema, edema, crusts, and itching. 26 Patient satisfaction with lesion clearance was assessed using the Patient Global Improvement Score (unchanged, >50% of lesions were healed, and all lesions were healed). Results show that 54% of patients treated with 5-FU reported all lesions to be healed in comparison with 20% of patients treated with DFS. 26 Despite the fact that patients treated with 5-FU experienced a significantly greater reduction in the number of lesions, DFS was better tolerated. 26 In a single-center, open-label, prospective, randomized controlled clinical trial of 200 patients, a comparison was drawn between treatment with diclofenac 3% plus hyaluronic acid gel (DHA) and MAL-PDT in adult Caucasian patients with skin types I-IV and at least five AKs of the face and scalp. 1 A visual analog scale was used to assess pain in MAL-PDT, and patients were asked to rate satisfaction as excellent (very satisfied), good (moderately satisfied), or fair (slightly or not satisfied). Results show that more patients treated with MAL-PDT were noted being very satisfied than those treated with DHA (59% versus 6%, p < 0.0001).
1

Light therapies and procedural modalities PDT
PDT involves the application of a photosensitizing drug to the skin surface. 29 The irradiation of the accumulated photosensitizing compound leads to the production of cytotoxic oxygen species that result in cell damage. 30 PDT therapy directly damages dysplastic cells, indirectly disrupts tumor vasculature, and activates an inflammatory response characterized by localized edema at the target site. 31, 32 Although there is a general lack of literature assessing patient satisfaction as it pertains to various treatment options for AK, the majority of information that does exist pertains to treatment with either IM or PDT. In a retrospective telephone survey of 24 patients with facial or scalp AK, 50% of patients thought PDT was very effective. 33 Patients selected for this study had PDT field therapy using either 160 mg/g MAL cream or generic compound 20% 5-aminolavulinic acid (5-ALA) solution. Pain during illumination was reported as a significant problem, with 58% of patients reporting severe pain. 33 Although 50% of respondents reported high efficacy, 70% of patients found PDT to be barely affordable. 33 Still, 66% of respondents said they would recommend PDT to others. 33 Among those who said they would not recommend the treatment were those patients who experienced moderate to severe side effects and those who were disappointed with their clearance relative to cost and pain.
In a Phase III, multicenter, randomized, investigatorblinded, controlled, intraindividual study that lasted 12 weeks, 
182
Khanna et al daylight PDT (DL-PDT) was compared to conventional PDT (c-PDT), revealing an instance where pain seemed to directly influence patient satisfaction. 34 Clinical trials support the success of c-PDT in effectively treating AK, especially in patients with AKs covering larger areas. 35 However, trials have found that c-PDT is associated with significant pain, especially when treating the face. 36 Growing literature also asserts that DL-PDT is less painful in comparison, on account of its different photoactivation. 34 Results of the trial of 108 subjects describe DL-PDT to be virtually painless compared to c-PDT (0.7 versus 4.4, p < 0.001), which was consistent with better tolerance and higher satisfaction for DL-PDT. 34 Overall, 64.8% of subjects were very satisfied with DL-PDT compared to 18.9% with c-PDT. More patients found DL-PDT to be very convenient when compared to those treated with c-PDT (53.8% versus 10.5%, respectively).
In another study, a questionnaire was mailed to 39 subjects, surveying for factors such as cost, effectiveness, treatment preference between PDT, 5-FU, and imiquimod as options, recovery time, and overall patient satisfaction. 37 Patients significantly preferred PDT to 5-FU (p < 0.001) and imiquimod (p = 0.031), and recovery time for PDT was 1 week or less when compared to cryotherapy (p = 0.02) and surgical excision (p = 0.02).
Cryotherapy
Cryotherapy is one of the most commonly used AK treatments and is performed by freezing individual AK lesions with liquid nitrogen delivered at -195.8°C. 37 Epidermal keratinocytes, which characteristically die at -40°C to -50°C, are destroyed by this freezing approach. 38 This quick and relatively simple therapeutic strategy is a common first-line approach for AK treatment. 39 In a multicenter randomized, intraindividual (right-left) study, 119 subjects from both genders participated in telephone calls at weeks 1 and 13 to assess patient overall preference and lesion response to cryotherapy in comparison with MAL-PDT. 40 Patient satisfaction was recorded on a five-point scale that ranged from 1 (very dissatisfied) to 5 (very satisfied). Results showed that patients preferred MAL-PDT to cryotherapy (49.2% versus 20.6%, p < 0.001), with >90% satisfied with MAL-PDT for effectiveness and scarring. 40 Still, 91.7% preferred cryotherapy to MAL-PDT with regard to the prolonged duration of treatment. 40 In another similar study lasting 24 weeks, 59% of patients (n = 121) preferred their new lesions to be treated with MAL-PDT, which was significantly higher than the 25% that preferred cryotherapy (p < 0.001). 41 However, there was no significant difference between the two treatment options in terms of patient perception of effectiveness. MAL-PDT was preferred to cryotherapy for comfort (60% versus 10%, p < 0.001), healing outcome (64% versus 6%, p < 0.001), and overall patient satisfaction (49% versus 20%, p < 0.001). Consistent with other findings, cryotherapy resulted in 20% more skin-related adverse events when compared to MAL-PDT. 42 
Conclusion
When assessing patient-perceived outcomes and management of AK, patient satisfaction and QoL are often used interchangeably. However, current literature discussing improvement in QoL is limited to either retrospective or observational studies and varies widely in terms of quantifiable criteria for satisfaction assessments (Supplementary material). 10 It is difficult to quantify patient satisfaction on account of the many factors that influence patient perception of treatment outcome and QoL. These factors include age, gender, location of lesions, cost, duration of treatment, adverse effects, tolerance, and efficacy. A small patient population or a homogeneous subject group in terms of race, age, and gender can therefore skew results. Oftentimes, patient satisfaction reflects a balance between these factors, a claim consistent in current findings. 10 Although there is a lack of literature assessing QoL specifically, current studies underscore the importance of pain, lesion clearance, and adverse effects to overall satisfaction scores. Pain may contribute to both treatment tolerance and adherence. Recent findings state that short-term therapies with prompt clearance of AEs promote adherence of treatment and are therefore preferred. 43 In many instances, patients may even opt to use the less effective treatment if they feel the other options are intolerable. Such was the case with patients who preferred cryotherapy to PDT and imiquimod. 23 When comparing patient satisfaction between different AK treatments, it is also important to parallel the various types of surveys used to quantify QoL. Among the studies discussed, telephone interviews were often utilized, as were the Skindex and TSQM surveys. In contrast to the Dermatology Life Quality Index (DLQI), the Skindex-16 dermatology survey mostly evaluates clinical severity and the TSQM evaluates satisfaction with the medication. 44 The DLQI also fails to assess factors such as fear of SCC, which would potentially show in the emotions subscale of the Skindex-16 survey. Still, it is questionable whether these surveys effectively capture fears such as that of recurrence. As a chronic disease, AK requires repeated treatments, especially during the second half of a patient's lifetime. 34 As such, it may even be useful to assess satisfaction by determining how willing patients are to repeat certain treatments and compare these numbers to 
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Patient satisfaction and reported outcomes those who are unwilling. Although literature on patient satisfaction is lacking for various AK treatment options, based on the studies that do exist, PDT and IM have the highest QoL ratings among patients.
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